Onco Wiki / Rote Flagge

Hochgradige MET-Verstärkung (MET/CEP7-Verhältnis ≥4,0 ODER mittlere GCN ≥10) bei metastasiertem NSCLC —...

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDRF-NSCLC-MET-AMP-ACTIONABLE
ArtWarnhinweis
Statusreviewed 2026-04-29 | pending_clinical_signoff
ErkrankungenDIS-NSCLC
QuellenSRC-ESMO-NSCLC-METASTATIC-2024 SRC-GEOMETRY-WOLF-2020 SRC-NCCN-NSCLC-2025

Ursprung der Roten Flagge

BegriffsbestimmungHigh-level MET amplification (MET/CEP7 ratio ≥4.0 OR mean GCN ≥10) in metastatic NSCLC — distinct from MET ex14 skipping. Two contexts: (1) De-novo MET-amp NSCLC (~1-5%) — capmatinib (GEOMETRY mono-1 high-amp cohort: ORR 40%, mPFS 5.5 mo; off-label expansion beyond ex14 label). (2) Acquired MET-amp post-osimertinib resistance in EGFR-mut NSCLC — osimertinib + savolitinib (SAVANNAH; not yet FDA- approved). Low-level amp (GCN 5-9) NOT actionable.
Klinische RichtungIntensivierung
Kategoriehigh-risk-biology
Schaltet AlgorithmusALGO-NSCLC-METASTATIC-2L

Logik auslösen

{
  "any_of": [
    {
      "finding": "met_amplification",
      "value": true
    },
    {
      "finding": "met_amplification",
      "value": "positive"
    },
    {
      "finding": "met_amp",
      "value": "positive"
    },
    {
      "finding": "met_cep7_ratio_ge_4",
      "value": true
    },
    {
      "finding": "met_gcn_ge_10",
      "value": true
    },
    {
      "finding": "met_status",
      "value": "amplified"
    }
  ],
  "type": "biomarker"
}

Anmerkungen

GEOMETRY mono-1 enrolled MET-amp cohort by GCN strata: GCN ≥10 cohort (high-amp) showed clinically meaningful response to capmatinib; GCN 6-9 cohort showed minimal benefit. Detection: FISH (Cappuzzo / Schildhaus criteria — MET/CEP7 ≥4 = high-level) preferred; NGS copy-number calls require assay-specific high-amp threshold. IHC alone is screening only — confirmation by FISH or NGS required. EGFR-mut NSCLC progressing on osimertinib: MET-amp is dominant non-T790M resistance mechanism; SAVANNAH (osi + savolitinib) showed ORR ~49% but not FDA-approved (covered indirectly by amivantamab + lazertinib via MET arm in MARIPOSA-2). Routes via ALGO-NSCLC-METASTATIC-2L step-10 area (parallel to MET ex14 — capmatinib regimen reused).

Verwendet von

Algorithmen